We provide you with 20 years of free, institutional-grade data for ADCT stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of ADCT. Explore the full financial landscape of ADCT stock.
| Reported Date | CIK | Ticker | Type |
|---|
ADC Therapeutics(NYSE:ADCT) 
ADC Therapeutics SA, a clinical-stage oncology-focused biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its lead product candidates are loncastuximab tesirine (ADCT-402), an ADC that is in a Phase II clinical tria...
Website: http://www.adctherapeutics.com
Founded: 2011
CEO: Christopher John Martin
Sector: Healthcare
Industry: Biotechnology
Share this website to your friends
The information provided in this report about ADCT stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.